The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape

Lyu, Liyang; Ye, Feng; Chen, Xin; Y, Hu

doi:10.1038/s41587-020-00749-8

Cited by 19 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, patent inventors applied for patent rights only in countries or regions where there was a potential market for the product [21]. Furthermore, not only Chinese enterprises led patents in China; for example, Tsumura & Co Ltd. of Japan led patents in China, which demonstrates the continued internationalization and appeal of the Chinese market [23,24]. Overall, capital entry is a positive sign for developers and governments [25], while companies offer dynamism to the development of CCF technology [26].…”

Section: Commercializationmentioning

confidence: 99%

WITHDRAWN: Patent landscape of Chinese Classical Formulas

Shi

Luo

Zhao

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundChinese Classical Formulas (經典名方, CCFs) are clinically employed formulas that have been documented in the literature since before the Ming era. In 2010, China began focusing on the development and product transformation of CCFs and issued a list of 100 CCFs as a reference. Patents are key components of the process for transferring technology to product; however, they are rarely employed in current CCF research. Therefore, the present study aims to explore the current situation of CCFs based on the China National Intellectual Property Administration (CNIPA) and provide a reference for researchers, investors, and policymakers to make relevant decisions. MethodsInformation on CCF publication numbers was obtained from the CNIPA, and data for patent applications made before June 30, 2021, on inventors, titles, and abstracts were searched in the patent database, Derwent Innovation. Duplicate application numbers were removed, applications were standardized, and inventors were categorized. The processed data were then used for subsequent analyses. ResultsA total of 287 patents were included in this analysis, and 61 CCFs were patented. Two major policies regarding CCFs in 2011 and 2019 greatly stimulated related patent applications, but lacked sustainability, followed by a relatively large decline in 2012 and 2020. Among the granted patents, 42.59% are analytical methods-related inventions and 24.07% for preparation methods. The percentage of core patents on substance basis and mechanism of action is relatively small. ConclusionPolicies have a significant impact on CCF R&D. The number of CCF patent applications is increasing every year and there is an increasing number of companies as patent applicants, which indicates that CCF is considered to have a good market potential. However, the lack of high quality patents may create difficulties for future development and this will be an important issue to be addressed. Keywords Chinese classical formulations, Chinese medicine, patent, product transformation

show abstract

Section: Commercializationmentioning

confidence: 99%

WITHDRAWN: Patent landscape of Chinese Classical Formulas

Shi

Luo

Zhao

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The citation network was also time sliced according to priority year to clearly trace the technological trajectories of siRNA delivery R&D, 27 and the most-cited patent family in each layer was regarded as its milestone patent. In Figure 7 B, these patents are displayed on a timeline with their patent numbers and English titles shown.…”

Section: Resultsmentioning

confidence: 99%

“… 24 Moreover, patent analysis can be used to underpin important decisions made by academics, industry leaders, and governments. 25 It has been successfully applied in many biological science fields, such as anti-Parkinson’s drugs 26 and chimeric antigen receptor T cell therapy, 27 to discover technological position, determine technical landmarks, and forecast technology development tendencies in a sector, technology domain, or company.…”

Section: Introductionmentioning

confidence: 99%

Delivery of therapeutic small interfering RNA: The current patent-based landscape

Chen

Xiong

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…Notably, CAR-T therapy with the most investigated target thus far, CD19, is a promising therapy for hematologic cancer and has dramatically improved the treatment of lymphoid malignancies, predominantly diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). Besides CD19, other common targets include B cell maturation antigen (BCMA), CD20, mesothelin (MSL), and PD-1/PD-L1 [1][2][3]. The CAR construct has become progressively more advanced over time.…”

Section: Introductionmentioning

confidence: 99%

Emerging Novel Combined CAR-T Cell Therapies

Nguyễn

Johanning²,

Shi

2022

Cancers

View full text Add to dashboard Cite

Chimeric antigen receptors (CAR) T cells are T cells engineered to express membrane receptors with high specificity to recognize specific target antigens presented by cancer cells and are co-stimulated with intracellular signals to increase the T cell response. CAR-T cell therapy is emerging as a novel therapeutic approach to improve T cell specificity that will lead to advances in precision medicine. CAR-T cells have had impressive outcomes in hematological malignancies. However, there continue to be significant limitations of these therapeutic responses in targeting solid malignancies such as heterogeneous antigens in solid tumors, tumor immunosuppressive microenvironment, risk of on-target/off-tumor, infiltrating CAR-T cells, immunosuppressive checkpoint molecules, and cytokines. This review paper summarizes recent approaches and innovations through combination therapies of CAR-T cells and other immunotherapy or small molecule drugs to counter the above disadvantages to potentiate the activity of CAR-T cells.

show abstract

The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape

Cited by 19 publications

References 20 publications

WITHDRAWN: Patent landscape of Chinese Classical Formulas

WITHDRAWN: Patent landscape of Chinese Classical Formulas

Delivery of therapeutic small interfering RNA: The current patent-based landscape

Emerging Novel Combined CAR-T Cell Therapies

Contact Info

Product

Resources

About